| Size | Price | |
|---|---|---|
| 100mg | ||
| Other Sizes |
| Targets |
Ginsenoside F3 targets immune signaling pathways, particularly those involved in cytokine regulation. It modulates oxidative-stress and inflammatory signaling rather than a single defined receptor. The compound increases the DNA binding activity of NF-κB induced by concanavalin A in isolated mouse spleen cells. It modulates PI3K/Akt and MAPK pathways to induce apoptosis and inhibit proliferation in cancer cells.
|
|---|---|
| ln Vitro |
In vitro, Ginsenoside F3 stimulates proliferation of spleen cells and increases levels of IL-2 and IFN-γ while decreasing levels of IL-4 and IL-10. It increases NF-κB DNA binding activity induced by ConA at 10 μM. The compound induces apoptosis and inhibits proliferation in various cancer cell lines by modulating PI3K/Akt and MAPK pathways. It exhibits antioxidant, anti-inflammatory, and cytoprotective activity.
|
| ln Vivo |
In vivo, Ginsenoside F3 exerts immune-enhancing activity by regulating type 1 and type 2 cytokine production. It enhances neuronal survival and protects against oxidative stress. The compound supports cardiovascular health by regulating lipid metabolism and preventing endothelial dysfunction. It has anticancer, neuroprotective, anti-inflammatory, and cardioprotective effects.
|
| Enzyme Assay |
In vitro enzyme assays for Ginsenoside F3 involve measuring its effects on cytokine production and NF-κB activation. Spleen cells are cultured and treated with the compound, and cytokine levels (IL-2, IFN-γ, IL-4, IL-10) are measured by ELISA. NF-κB DNA binding activity is assessed by electrophoretic mobility shift assay (EMSA). For anticancer studies, cancer cell lines are treated with the compound and cell viability and apoptosis are assessed.
|
| Cell Assay |
In vitro cell-based assays for Ginsenoside F3 are conducted in murine spleen cells and cancer cell lines. Spleen cells are isolated and cultured in appropriate media, then treated with the compound at varying concentrations. Cytokine production is measured by ELISA. NF-κB activation is assessed by EMSA. Cancer cell lines are treated with the compound and cell viability is assessed by MTT or CCK-8 assays. Apoptosis is evaluated by Annexin V/PI staining.
|
| Animal Protocol |
Ginsenoside F3 in vivo studies are conducted in animal models for immunomodulation, cancer, and neuroprotection. Animals are treated with Ginsenoside F3 via oral administration or injection. Immune responses are assessed by measuring cytokine levels and immune cell populations. For cancer studies, tumor-bearing mice are used and tumor growth is monitored. For neuroprotection studies, animal models of neurodegeneration are used. Animals are monitored for clinical signs. Tissues and blood samples are collected for histopathological and biomarker analysis.
|
| ADME/Pharmacokinetics |
Ginsenoside F3 (MW 770.99 g/mol, C41H70O13) has a purity of ≥95%. It is a protopanaxatriol-type saponin isolated from Panax ginseng leaves. The compound is soluble in DMSO and other organic solvents. It is stable under recommended storage conditions. Pharmacokinetic parameters such as half-life, bioavailability, and tissue distribution would be determined in species-specific studies.
|
| Toxicity/Toxicokinetics |
Ginsenoside F3 is generally well-tolerated in preclinical studies. The compound is a natural saponin from Panax ginseng with established safety profiles. Its immunomodulatory, anticancer, neuroprotective, and anti-inflammatory effects have been demonstrated with acceptable safety profiles. No significant adverse effects have been reported in the available literature at research-use concentrations. The compound is intended for research use only. Standard safety precautions should be followed when handling. Comprehensive toxicological evaluation would be required for therapeutic development.
|
| References | |
| Additional Infomation |
Ginsenoside F3 is a triterpenoid saponin. It has been reported that ginseng and eleuthero contain ginsenoside F3, and relevant data are available for reference.
Ginsenoside F3 is a protopanaxatriol-type saponin from Panax ginseng leaves with immune-enhancing activity. It regulates type 1 (IL-2, IFN-γ) and type 2 (IL-4, IL-10) cytokine production and enhances NF-κB DNA binding activity. The compound exhibits anticancer, neuroprotective, anti-inflammatory, and cardioprotective effects, modulating PI3K/Akt and MAPK pathways. Its molecular formula is C41H70O13 with a molecular weight of 770.99 g/mol.All applications are limited to non-human research use. |
| Molecular Formula |
C41H70O13
|
|---|---|
| Molecular Weight |
770.9867
|
| Exact Mass |
770.481
|
| CAS # |
62025-50-7
|
| PubChem CID |
46887678
|
| Appearance |
White to off-white solid powder
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
873.3±65.0 °C at 760 mmHg
|
| Flash Point |
481.9±34.3 °C
|
| Vapour Pressure |
0.0±0.6 mmHg at 25°C
|
| Index of Refraction |
1.597
|
| LogP |
5.67
|
| Hydrogen Bond Donor Count |
9
|
| Hydrogen Bond Acceptor Count |
13
|
| Rotatable Bond Count |
9
|
| Heavy Atom Count |
54
|
| Complexity |
1360
|
| Defined Atom Stereocenter Count |
20
|
| SMILES |
CC(=CCC[C@@](C)([C@H]1CC[C@@]2([C@@H]1[C@@H](C[C@H]3[C@]2(C[C@@H]([C@@H]4[C@@]3(CC[C@@H](C4(C)C)O)C)O)C)O)C)O[C@H]5[C@@H]([C@H]([C@@H]([C@H](O5)CO[C@H]6[C@@H]([C@H]([C@H](CO6)O)O)O)O)O)O)C
|
| InChi Key |
HJRVLGWTJSLQIG-ABNMXWHVSA-N
|
| InChi Code |
InChI=1S/C41H70O13/c1-20(2)10-9-13-41(8,54-36-33(50)31(48)30(47)25(53-36)19-52-35-32(49)29(46)24(44)18-51-35)21-11-15-39(6)28(21)22(42)16-26-38(5)14-12-27(45)37(3,4)34(38)23(43)17-40(26,39)7/h10,21-36,42-50H,9,11-19H2,1-8H3/t21-,22+,23-,24-,25+,26+,27-,28-,29-,30+,31-,32+,33+,34-,35-,36-,38+,39+,40+,41-/m0/s1
|
| Chemical Name |
(2S,3R,4S,5S,6R)-2-[(2S)-6-methyl-2-[(3S,5R,6S,8R,9R,10R,12R,13R,14R,17S)-3,6,12-trihydroxy-4,4,8,10,14-pentamethyl-2,3,5,6,7,9,11,12,13,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl]hept-5-en-2-yl]oxy-6-[[(2S,3R,4S,5S)-3,4,5-trihydroxyoxan-2-yl]oxymethyl]oxane-3,4,5-triol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~129.70 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (3.24 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (3.24 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (3.24 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.2970 mL | 6.4852 mL | 12.9703 mL | |
| 5 mM | 0.2594 mL | 1.2970 mL | 2.5941 mL | |
| 10 mM | 0.1297 mL | 0.6485 mL | 1.2970 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
